Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1979 Apr;63(4):727–735. doi: 10.1172/JCI109356

Effects of Metoclopramide and Bromocriptine on the Renin-Angiotensin-Aldosterone System in Man

DOPAMINERGIC CONTROL OF ALDOSTERONE

Robert M Carey 1, Michael O Thorner 1, Elizabeth M Ortt 1
PMCID: PMC372008  PMID: 438333

Abstract

This study was designed to investigate the possible role of dopaminergic mechanisms in the control of the renin-angiotensin-aldosterone system in normal man. Six normal male subjects in metabolic balance at 150 meq sodium, 60 meq potassium constant intake received the specific dopamine antagonist, metoclopramide, 10 mg i.v. or placebo followed by angiotensin II infusion 1 h later on 2 consecutive days. Metoclopramide increased plasma aldosterone concentration from 8.2±2.2 to 21.0±3.3 ng/100 ml (P < 0.005) and plasma prolactin concentration from 18.0±4.0 to 91.7±4.0 ng/ml (P < 0.001) within 15 min of its administration. At 1 h, plasma aldosterone and prolactin concentrations remained elevated at 16.8±2.1 ng/100 ml (P < 0.01) and 86.8±15.9 ng/ml (P < 0.005), respectively. Angiotensin II at 2, 4, and 6 pmol/kg per min further increased plasma aldosterone concentration to 27.2±3.4, 31.9±5.7, and 36.0±6.7 ng/100 ml (P < 0.02), respectively. Placebo did not alter plasma aldosterone or prolactin concentrations, but angiotensin II increased plasma aldosterone concentration to 13.7±2.4, 19.0±1.9, and 23.3±3.2 ng/100 ml (P < 0.005). The increment of plasma aldosterone concentration in response to angiotensin II was similar after metoclopramide or placebo.

The six subjects also received the dopamine agonist, bromocriptine, 2.5 mg or placebo at 6 p.m., midnight, and 6 a.m. followed by angiotensin II infusion on 2 consecutive d. Bromocriptine suppressed prolactin to <3 ng/ml. After placebo, plasma aldosterone concentration increased from 5.2±1.4 to 12.3±1.7, 17.2±2.2, and 21.8±3.5 ng/100 ml (P < 0.01) and after bromocriptine from 7.2±1.0 to 14.7±3.0, 19.8±3.2, and 23.4±1.6 ng/100 ml (P < 0.001) with each respective angiotensin II dose. No difference in the response to angiotensin II after bromocriptine or placebo was observed. Plasma renin activity, free 11-hydroxycorticoid concentration, and serum potassium concentration were unchanged by metoclopramide or bromocriptine.

The results suggest that aldosterone production is under maximum tonic dopaminergic inhibition which can be overridden with stimulation by angiotensin II in normal man.

Full text

PDF
727

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham S. F., Blair-West J. R., Coghlan J. P., Denton D. A., Mouw D. R., Scoggins B. A. Aldosterone secretion during high sodium cerebrospinal fluid perfusion of the brain ventricles. Acta Endocrinol (Copenh) 1976 Jan;81(1):120–132. doi: 10.1530/acta.0.0810120. [DOI] [PubMed] [Google Scholar]
  2. Alexander R. W., Gill J. R., Jr, Yamabe H., Lovenberg W., Keiser H. R. Effects of dietary sodium and of acute saline infusion on the interrelationship between dopamine excretion and adrenergic activity in man. J Clin Invest. 1974 Jul;54(1):194–200. doi: 10.1172/JCI107743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baumann G., Loriaux D. L. Failure of endogenous prolactin to alter renal salt and water excretion and adrenal function in man. J Clin Endocrinol Metab. 1976 Sep;43(3):643–649. doi: 10.1210/jcem-43-3-643. [DOI] [PubMed] [Google Scholar]
  4. Besser G. M., Parke L., Edwards C. R., Forsyth I. A., McNeilly A. S. Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Br Med J. 1972 Sep 16;3(5828):669–672. doi: 10.1136/bmj.3.5828.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bunag R. D., Page I. H., McCubbin J. W. Neural stimulation of release of renin. Circ Res. 1966 Oct;19(4):851–858. doi: 10.1161/01.res.19.4.851. [DOI] [PubMed] [Google Scholar]
  6. Burwell L. R., Davis W. W., Bartter F. C. Studies on the loci of action of stimuli to the biogenesis of aldosterone. Proc R Soc Med. 1969 Dec 12;62(12):1254–1257. doi: 10.1177/003591576906201225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clark B. J., Scholtysik G., Flückiger E. Cardiovascular actions of bromocriptine. Acta Endocrinol Suppl (Copenh) 1978;216:75–81. [PubMed] [Google Scholar]
  8. Corrodi H., Fuxe K., Hökfelt T., Lidbrink P., Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol. 1973 May;25(5):409–412. doi: 10.1111/j.2042-7158.1973.tb10037.x. [DOI] [PubMed] [Google Scholar]
  9. Cuche J. L., Kuchel O., Barbeau A., Boucher R., Genest J. Relationship between the adrenergic nervous system and renin during adaptation to upright posture: a possible role for 3,4-dihydroxyphenethylamine (dopamine). Clin Sci. 1972 Oct;43(4):481–491. doi: 10.1042/cs0430481. [DOI] [PubMed] [Google Scholar]
  10. Day M. D., Blower P. R. Cardiovascular dopamine receptor stimulation antagonized by metoclopramide. J Pharm Pharmacol. 1975 Apr;27(4):276–278. doi: 10.1111/j.2042-7158.1975.tb10699.x. [DOI] [PubMed] [Google Scholar]
  11. Delitala G., Masala A., Alagna S., Devilla L. Effect of metroclopramide on serum prolactin levels in humans. Clin Endocrinol (Oxf) 1976 Nov;5(6):731–734. doi: 10.1111/j.1365-2265.1976.tb03877.x. [DOI] [PubMed] [Google Scholar]
  12. Denton D. A., Blair-West J. R., Coghlan J. P., Scoggins B. A., Wright R. D. Gustatory-alimentary reflex inhibition of aldosterone hypersecretion by the autotransplanted adrenal gland of sodium deficient sheep. Acta Endocrinol (Copenh) 1977 Jan;84(1):119–132. doi: 10.1530/acta.0.0840119. [DOI] [PubMed] [Google Scholar]
  13. Edwards C. R., Miall P. A., Hanker J. P., Thorner M. O., Al-Dujaili E. A., Besser G. M. Inhibition of the plasma-aldosterone response to frusemide by bromocriptine. Lancet. 1975 Nov 8;2(7941):903–905. doi: 10.1016/s0140-6736(75)92132-7. [DOI] [PubMed] [Google Scholar]
  14. Flückiger E., Wagner H. R. 2-Br-alpha-Ergokryptin: Beeinflussung von Fertilität und Laktation bei der Ratte. Experientia. 1968 Nov 15;24(11):1130–1131. doi: 10.1007/BF02147804. [DOI] [PubMed] [Google Scholar]
  15. Fuxe K., Corrodi H., Hökfelt T., Lidbrink P., Ungerstedt U. Ergocornine and 2-Br-alpha-ergocryptine. Evidence for prolonged dopamine receptor stimulation. Med Biol. 1974 Apr;52(2):121–132. [PubMed] [Google Scholar]
  16. Goldstein M., Lieberman A., Battista A. F., Lew J. Y., Matsumoto Y. Experimental and clinical studies on bromocriptine in the Parkinsonian syndrome. Acta Endocrinol Suppl (Copenh) 1978;216:57–66. [PubMed] [Google Scholar]
  17. Gordon R. D., Küchel O., Liddle G. W., Island D. P. Role of the sympathetic nervous system in regulating renin and aldosterone production in man. J Clin Invest. 1967 Apr;46(4):599–605. doi: 10.1172/JCI105561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Holland O. B., Gomez-Sanchez C. E., Kem D. C., Weinberger M. H., Kramer N. J., Higgins J. R. Evidence against prolactin stimulation of aldosterone in normal human subjects and patients with primary aldosteronism, including a patient with primary aldosteronism and a prolactin-producing pituitary microadenoma. J Clin Endocrinol Metab. 1977 Nov;45(5):1064–1076. doi: 10.1210/jcem-45-5-1064. [DOI] [PubMed] [Google Scholar]
  19. MATTINGLY D. A simple fluorimetric method for the estimation of free 11-hydroxycorticoids in human plasma. J Clin Pathol. 1962 Jul;15:374–379. doi: 10.1136/jcp.15.4.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McNeilly A. S., Thorner M. O., Volans G., Besser G. M. Letter: Metaclopramide and prolactin. Br Med J. 1974 Jun 29;2(5921):729–729. doi: 10.1136/bmj.2.5921.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Norbiato G., Bevilacqua M., Raggi U., Micossi P., Moroni C. Metoclopramide increases plasma aldosterone concentration in man. J Clin Endocrinol Metab. 1977 Dec;45(6):1313–1316. doi: 10.1210/jcem-45-6-1313. [DOI] [PubMed] [Google Scholar]
  22. Ogihara T., Matsumura S., Onishi T., Miyai K., Uozumi T. Effect of metoclopramide-induced prolactin on aldosterone secretion in normal subjects. Life Sci. 1977 Feb 1;20(3):523–526. doi: 10.1016/0024-3205(77)90396-4. [DOI] [PubMed] [Google Scholar]
  23. Olgaard K., Hagen C., Madsen S., Hummer L. Lack of effect of prolactin inhibition by alpha-bromoergocriptine (CB 154) on plasma aldosterone in anephric and non-nephrectomized patients on regular haemodialysis. Acta Endocrinol (Copenh) 1977 Jul;85(3):587–594. doi: 10.1530/acta.0.0850587. [DOI] [PubMed] [Google Scholar]
  24. Peringer E., Jenner P., Marsden C. D. Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5-hydroxytryptamine. J Pharm Pharmacol. 1975 Jun;27(6):442–444. doi: 10.1111/j.2042-7158.1975.tb09477.x. [DOI] [PubMed] [Google Scholar]
  25. Sinha Y. N., Selby F. W., Lewis U. J., VanderLaan W. P. A homologous radioimmunoassay for human prolactin. J Clin Endocrinol Metab. 1973 Mar;36(3):509–516. doi: 10.1210/jcem-36-3-509. [DOI] [PubMed] [Google Scholar]
  26. Thorner M. O. Dopamine is an important neurotransmitter in the autonomic nervous system. Lancet. 1975 Mar 22;1(7908):662–665. doi: 10.1016/s0140-6736(75)91762-6. [DOI] [PubMed] [Google Scholar]
  27. Valenzuela J. E. Dopamine as a possible neurotransmitter in gastric relaxation. Gastroenterology. 1976 Dec;71(6):1019–1022. [PubMed] [Google Scholar]
  28. Wartofsky L., Burman K. D., Dimond R. C., Noel G. L., Frantz A. G., Earll J. M. Studies on the nature of thyroidal suppression during acute falciparum malaria: integrity of pituitary response to TRH and alterations in serum T3 and reverse T3. J Clin Endocrinol Metab. 1977 Jan;44(1):85–90. doi: 10.1210/jcem-44-1-85. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES